European Leukemia Trial Registry
Trial: MDS 5-azacitidine (Vidaza)

More Details
Scientific Title Treatment of imminent haematological relapse in patients with AML and MDS following allogeneic stem cell transplantation with 5-azacitidine (Vidaza®)
Short Title MDS 5-azacitidine (Vidaza)
Trialgroup NN
Type of Trial prospective, open-label, pilot study
Disease Stem cell transplantation(SCT) AML
Acute myeloid leukemia(AML) Stem cell transplantation
Stem cell transplantation(SCT) MDS
Myelodysplastic Syndrome(MDS) Stem cell transplantation
Age >= 18 years
Status Closed
Start of Recruitment 19.10.2006
Leader Platzbecker, Prof. Dr. med., Uwe

Study Physician
Weller, Dr. med., Denise
Tel: +49 (0)351 458 5134
Fax: +49 (0)351 458 5799

Schwanebeck, Uta
Tel: +49 (0)351 458 5134

Centre of Trial Universitätsklinikum Carl Gustav Carus, Dresden
Shortprotocol Shortprotocol
Remark Inclusion only for patients with CD34 pos. AML or MDS
created 05.03.2007 Deniz Gökbuget
changed 05.11.2014 Alexandra Lucaciu
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | |